cause widespread havoc to the patient's physiology, towards a more specific and gentler, patient-tailored approach. Converting cancer into a chronic, controllable illness now seems to be a distinct possibility. But we're not quite there yet.
The tensions between the medical community, the research funders and institutes, the US Food and Drug Administration, the pharmaceutical industry and the taxpayers have dramatically increased and are well outlined by Nathan. He clearly doesn't like the politics -stating "science policy in the Bush administration can only be described as absurd and dangerous". Wonderful stuff -in some countries he could find himself without a job, in others in jail for treason and in a few just disappear. But I'm sure most readers would like some elaboration. Nonetheless, there is no doubt that the United States has committed huge amounts of money to the war on cancer. Whether it has been a worthwhile quest remains to be seen but, as Nathan points out, it has heavily subsidized the entire biomedical research endeavour.
The biggest difficulty with this book is working out exactly who it is written for. Most patients and their carers would find it scientifically too demanding. Even with its glossary, the vocabulary is more for a Nature subscriber than a newspaper reader. Most of it would be simply irrelevant to any individual with cancer -of the three detailed case histories covered, two are about extremely rare conditions (gastrointestinal stromal tumour and mixedlineage leukaemia). The emotional content all seems a little hollow -almost as though it's been added as an afterthought. Doctors on the whole shudder when they see a chapter headed "Ken's story". We tend to try to box off the human side of disease so we can get on with the business in hand: doing the best we can to cure or prolong life. When we read about the science of cancer we want it unbundled from the fear, concern and hope. There are plenty of excellent psychosocial texts around. And patients prefer a much more user-friendly and less technical communication style tailored to their precise clinical problem. There are some excellent examples of this genre from various cancer charities on both sides of the Atlantic as well as Adam Wishart's One in Three (Profile Books, 2006) or Rosy Daniel's "Cancer Lifeline Kit" (www.healthcreation.co.uk/kit.htm).
Maybe senior academic physicians should stick to writing about the science of cancer treatment and get others to do the popularization. Currently, the alternative medicine movement dominates the bookstore shelves on cancer. Wacky diets, bizarre relaxation exercises, crank healers and of course herbal remedies all promise a cure without any side effects. These texts are inspirational, conclusive and positive. In an era of patient choice, that seems to be what the customers really want. So while I enjoyed and learned a lot from this great account of the wonderful achievements of science and medicine, I feel it is unlikely to be a bestseller at the airport. 
